Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David N Rush

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
BMJ Open|April 13, 2019
Multicentre randomised controlled trial protocol of urine CXCL10 monitoring strategy in kidney transplant recipientsJulie Ho, Atul Sharma, Kristine Kroeker, et al.
Transplantation Direct|January 29, 2025
Epidemiology of Epstein-Barr Virus Chronic High Viral Load in Kidney Transplant RecipientsChristie Rampersad, Chris Wiebe, Robert Balshaw, et al.
Human Immunology|July 17, 2025
HLA-DQ heterodimer mismatch as a predictor of post-transplant alloimmunity and allograft survivalEmmett Tsz Yeung Wong, Robert Balshaw, Ian W Gibson, et al.
Journal of the American Society of Nephrology : JASN|May 7, 2026
Microvascular Inflammation in Kidney TransplantationEmmett Tsz Yeung Wong, Robert Balshaw, Ian W Gibson, et al.
Transplantation|May 4, 2026
Declining All-cause Allograft Survival in the Modern era: A 50-y Single-center Consecutive Cohort StudyElijah Wiebe, Robert Balshaw, Kaleb Chartier, et al.
Journal of the American Society of Nephrology : JASN|July 22, 2017
Class II Eplet Mismatch Modulates Tacrolimus Trough Levels Required to Prevent Donor-Specific Antibody DevelopmentChris Wiebe, David N Rush, Thomas E Nevins, et al.
Transplantation|November 26, 2009
Factors associated with progression of interstitial fibrosis in renal transplant patients receiving tacrolimus and mycophenolate mofetilDavid N Rush, Sandra M Cockfield, Peter W Nickerson, et al.
Clinical Transplantation|May 9, 2024
Association of BKV viremia and nephropathy with adverse alloimmune outcomes in kidney transplant recipientsChristie Rampersad, Chris Wiebe, Robert Balshaw, et al.
Clinical Transplantation|December 31, 2024
A Five-Year Prospective, Randomized, Open-Label Study of Standard-Dose Versus Low-Dose Prolonged-Release Tacrolimus With or Without Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker Post Kidney TransplantationPatricia M Campbell, Marcelo Cantarovich, Azim Gangji, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|December 25, 2018
Comparison of the effects of standard vs low-dose prolonged-release tacrolimus with or without ACEi/ARB on the histology and function of renal allograftsSandra M Cockfield, Sam Wilson, Patricia M Campbell, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
BMJ Open|April 13, 2019
Multicentre randomised controlled trial protocol of urine CXCL10 monitoring strategy in kidney transplant recipientsJulie Ho, Atul Sharma, Kristine Kroeker, et al.
Transplantation Direct|January 29, 2025
Epidemiology of Epstein-Barr Virus Chronic High Viral Load in Kidney Transplant RecipientsChristie Rampersad, Chris Wiebe, Robert Balshaw, et al.
Human Immunology|July 17, 2025
HLA-DQ heterodimer mismatch as a predictor of post-transplant alloimmunity and allograft survivalEmmett Tsz Yeung Wong, Robert Balshaw, Ian W Gibson, et al.
Journal of the American Society of Nephrology : JASN|May 7, 2026
Microvascular Inflammation in Kidney TransplantationEmmett Tsz Yeung Wong, Robert Balshaw, Ian W Gibson, et al.
Transplantation|May 4, 2026
Declining All-cause Allograft Survival in the Modern era: A 50-y Single-center Consecutive Cohort StudyElijah Wiebe, Robert Balshaw, Kaleb Chartier, et al.
Journal of the American Society of Nephrology : JASN|July 22, 2017
Class II Eplet Mismatch Modulates Tacrolimus Trough Levels Required to Prevent Donor-Specific Antibody DevelopmentChris Wiebe, David N Rush, Thomas E Nevins, et al.
Transplantation|November 26, 2009
Factors associated with progression of interstitial fibrosis in renal transplant patients receiving tacrolimus and mycophenolate mofetilDavid N Rush, Sandra M Cockfield, Peter W Nickerson, et al.
Clinical Transplantation|May 9, 2024
Association of BKV viremia and nephropathy with adverse alloimmune outcomes in kidney transplant recipientsChristie Rampersad, Chris Wiebe, Robert Balshaw, et al.
Clinical Transplantation|December 31, 2024
A Five-Year Prospective, Randomized, Open-Label Study of Standard-Dose Versus Low-Dose Prolonged-Release Tacrolimus With or Without Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker Post Kidney TransplantationPatricia M Campbell, Marcelo Cantarovich, Azim Gangji, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|December 25, 2018
Comparison of the effects of standard vs low-dose prolonged-release tacrolimus with or without ACEi/ARB on the histology and function of renal allograftsSandra M Cockfield, Sam Wilson, Patricia M Campbell, et al.
Pageof 4